These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol. Miyasaka Y; Ohtsuka T; Eguchi S; Inomata M; Nishihara K; Shinchi H; Okuda K; Baba H; Nagano H; Ueki T; Noshiro H; Nakamura M; Int J Surg Protoc; 2021 Apr; 25(1):55-60. PubMed ID: 34013145 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251 [TBL] [Abstract][Full Text] [Related]
5. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of defining borderline resectable pancreatic cancer. Kang MJ; Jang JY; Kwon W; Kim SW Pancreatology; 2018 Mar; 18(2):139-145. PubMed ID: 29274720 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Trial (JASPAC05). Takahashi S; Ohno I; Ikeda M; Konishi M; Kobayashi T; Akimoto T; Kojima M; Morinaga S; Toyama H; Shimizu Y; Miyamoto A; Tomikawa M; Takakura N; Takayama W; Hirano S; Otsubo T; Nagino M; Kimura W; Sugimachi K; Uesaka K Ann Surg; 2022 Nov; 276(5):e510-e517. PubMed ID: 33065644 [TBL] [Abstract][Full Text] [Related]
9. Borderline resectable pancreatic cancer: More than an anatomical concept. Petrelli F; Inno A; Barni S; Ghidini A; Labianca R; Falconi M; Reni M; Cascinu S; Dig Liver Dis; 2017 Feb; 49(2):223-226. PubMed ID: 27931968 [TBL] [Abstract][Full Text] [Related]
10. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658 [TBL] [Abstract][Full Text] [Related]
11. Endoscopic ultrasonography complements computed tomography in predicting portal or superior mesenteric vein resection in patients with borderline resectable pancreatic carcinoma. Glazer ES; Rashid OM; Klapman JB; Harris CL; Hodul PJ; Pimiento JM; Malafa MP Pancreatology; 2017; 17(1):130-134. PubMed ID: 28043760 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy? Versteijne E; de Hingh IHJT; Homs MYV; Intven MPW; Klaase JM; van Santvoort HC; de Vos-Geelen J; Wilmink JW; van Tienhoven G Front Oncol; 2021; 11():744161. PubMed ID: 35237500 [TBL] [Abstract][Full Text] [Related]
13. "Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer. Lombardi P; Silvestri S; Marino D; Santarelli M; Campra D; De Paolis P; Aglietta M; Leone F; Crit Rev Oncol Hematol; 2019 Jan; 133():17-24. PubMed ID: 30661653 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581 [TBL] [Abstract][Full Text] [Related]
15. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490 [TBL] [Abstract][Full Text] [Related]
16. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876 [TBL] [Abstract][Full Text] [Related]
17. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. He J; Schulick RD; Del Chiaro M Ann Surg Oncol; 2021 Mar; 28(3):1514-1520. PubMed ID: 33415556 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials. Hajibandeh S; Hajibandeh S; Intrator C; Hassan K; Sehmbhi M; Shah J; Mazumdar E; Kausar A; Satyadas T Ann Hepatobiliary Pancreat Surg; 2023 Feb; 27(1):28-39. PubMed ID: 36536501 [TBL] [Abstract][Full Text] [Related]
19. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Okada K; Kawai M; Hirono S; Satoi S; Yanagimoto H; Ioka T; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H Cancer Chemother Pharmacol; 2016 Oct; 78(4):719-26. PubMed ID: 27501851 [TBL] [Abstract][Full Text] [Related]
20. The role of neoadjuvant therapy in pancreatic cancer: a review. Russo S; Ammori J; Eads J; Dorth J Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]